Research summaries
Plain-English synopses of the published evidence behind longevity peptide biology. Each entry surveys the literature around a single research thread — mechanism, key papers, current gaps and the practical implications for laboratory research.
Telomere biology and the case for AEDG-class peptides in 2026
Telomere shortening remains one of the more clearly characterised hallmarks of ageing. Where does the AEDG short-peptide programme sit in the current evidence picture?
Mitochondrial peptides: state of the evidence in 2026
Three compounds dominate the mitochondrial peptide literature in 2026: Humanin, MOTS-c and SS-31. Where does each one stand?
GH-axis peptides and the IGF-1 longevity paradox
GHRH-axis peptides restore youthful IGF-1 profiles in older adults. But lower IGF-1 is associated with longer lifespan. How do we reconcile?
Immunosenescence and the case for thymic peptide research
Immunosenescence is one of the more clearly characterised ageing hallmarks. Thymic peptides — particularly Thymosin Alpha-1 — are among the few clinical-stage interventions on the table.
The Khavinson short-peptide programme: 40 years on
Four decades of Khavinson-group short-peptide research. The programme stands at a curious junction in 2026.
UK regulatory status of research peptides — a practitioner's reference
A practical reference on UK regulatory status of research peptides in 2026: MHRA, Medicines Regulations, the 'research chemical' framing.